Orthopedic Regenerative Medicine Market, by Treatment Type (Stem Cell Therapy (Allogeneic Bones, Autogeneic Bones, and Bone Grafting), Plasma Based Therapy, Tissue Engineering (Allograft)), by Disease Indication (Osteoarticular Diseases, Rheumatoid Arthri

Orthopedic Regenerative Medicine Market, by Treatment Type (Stem Cell Therapy (Allogeneic Bones, Autogeneic Bones, and Bone Grafting), Plasma Based Therapy, Tissue Engineering (Allograft)), by Disease Indication (Osteoarticular Diseases, Rheumatoid Arthritis, Ligament Injuries, Bursitis, and Osteoporosis), by End User (Hospital and Clinics, Orthopedic Specialty Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Regenerative medicines can be consider as manufacturing of pharmaceuticals for the regrowth of cells, replacing damaged cells, organs, or tissues .The developing methods for medicines includes the generation, tissue engineering, and therapeutic stem cells and production of artificial organs. Regenerative orthopedic medicines can help in healing damaged tissues, and improve the discomfort and pain which occurred due to musculoskeletal diseases. These regenerative medicines can be developed by using stem cells, plasma-rich sources, biological tissues, and bone marrow. Orthopedic regenerative medicines help in healing injuries of ligament, tendon, bone, spinal disc, muscle, cartilage, and musculoskeletal tissues.
Market Dynamics
Market players are indulged in receiving approvals from regulatory authorities for the treatment of orthopedic diseases, which is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, on June 28, 2021, Curasan AG, a company which produce regenerative medicines, has received approval from U.S. Food and Drug Administration (FDA) and The National Health Surveillance Agency (ANVISA) Brazilian regulatory agency for CERASORB Foam for use with antibiotics which is a β-TCP collagen matrix which use for delivering antimicrobials to wound surface to inhibit microbes capable of healing. The major use of this foam is minimizing the risk of reinfection of the infected area by combining it with antibiotics.
Increasing inorganic activities by market players such as collaborations, partnerships, and agreements is expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, on January 14, 2021, Bone Therapeutics, which is a manufacturer of cell therapy products, signed partnership with Rigener and, a company which develops and produces cGMP products, used for cell-gene therapy. The aim of this partnership was to develop products based on bone therapeutics by expanding research for therapeutic portfolio. This partnership will be focused on augmented bone forming cells that are programmed for specific task and by studying the new mechanisms of action for gene modifications for orthopedic regenerative medicines.
Key features of the study:
This report provides an in-depth analysis of the global orthopedic regenerative medicine market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global orthopedic regenerative medicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study includes Ortho Regenerative Technologies Inc., Personalized stem cells Inc., Anika Therapeutics Inc., Arthrex Inc., Baxter International Inc., Conmed Corporation, Aziyo Biologics, Curasan Inc., Swiss biomed Orthopedics AG, Octane Medical Inc., Stryker Corporation, Carmell Therapeutics Corporation, Zimmer Holdings, Smith & Nephew plc., and NuVasive Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global orthopedic regenerative medicine market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global orthopedic regenerative medicine market
Detailed Segmentation:
Global Orthopedic Regenerative Medicine Market, By Treatment Type :
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
Global Orthopedic Regenerative Medicine Market, By Disease Indication:
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
Global Orthopedic Regenerative Medicine Market, By End User :
Hospitals and Clinics
Orthopedic Specialty Centers
Others
Global Orthopedic Regenerative Medicine Market, By Region:
North America
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic Specialty Centers
Others
By Country:
U.S.
Canada
Latin America
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic Specialty Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic Specialty Centers
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic Specialty Centers
Others
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic Specialty Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type:
Stem Cell Therapy
Allogeneic Bones
Autogeneic Bones
Bone Grafting
Plasma Based Therapy
Tissue Engineering
Allograft
By Disease Indication :
Osteoarticular Diseases
Rheumatoid Arthritis
Ligament Injuries
Bursitis
Osteoporosis
By End User:
Hospitals and Clinics
Orthopedic specialty centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Ortho Regenerative Technologies Inc. *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Personalized stem cells Inc.
Anika Therapeutics Inc.
Arthrex Inc.
Baxter International Inc.
Conmed Corporation
Aziyo Biologics
Curasan Inc.
Swiss biomed Orthopedics AG
Octane Medical Inc.
Stryker Corporation
Carmell Therapeutics Corporation
Zimmer Holdings
Smith & Nephew plc.
NuVasive Inc.

“*” marked represents similar segmentation in other categories in the respective section.